Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer

Lancet Oncology

Volumn 5, Issue 6, 2004, Pages 372-380

  Nowak, Anna K ^a   Wilcken, N R C ^a   Stockler, M R ^a,b   Hamilton, A ^b   Ghersi, D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PREDNISOLONE; PROTEIN P53; TAXANE DERIVATIVE; VINCRISTINE;

AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CARDIOTOXICITY; CLINICAL STUDY; CLINICAL TRIAL; DRUG RESPONSE; EARLY CANCER; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HEART FAILURE; HUMAN; LEUKEMIA; LYMPH NODE METASTASIS; MYALGIA; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; PATHOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 2542422890     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01494-9     Document Type: Review

References (23)

1. Bishop JF Dewar J Toner GC et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer J Clin Oncol 17 1999 2355-2364
2. Chan S, Friedrichs K, Noel D, et al, for the 303 study group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-354.
3. Ghersi D, WN, Simes J. Taxanes for metastatic breast cancer. In: The Cochrane Library. Issue 3. Oxford: Update Software 2003.
4. Parmar MK Torri V Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815-2834
5. Bear HD Anderson S Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 2003 4165-4174
6. Buzdar AU Singletary SE Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer J Clin Oncol 17 1999 3412-3417
7. Malamos NK Kosmas C Antonopoulos MJ et al. Prospective randomized study of neoadjuvant chemotherapy with paclitaxel/epirubicin versus fluorouracil/epirubicin/cyclophosphamide in operable stage II-IIIA breast cancer Ann Oncol 9 (suppl) 1998 22
8. Smith IC Heys SD Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 2002 1456-1466
9. Vinholes J, Bouzid K, Salas F, et al. Preliminary results of a multicentre phase III trial of taxotere and doxorubicin verus 5-fluorouracil, doxorubicin and cyclophosphamide in patients with unresectable locally advanced breast cancer. Proc Am Soc Clin Oncol 2001; 20: abstr 101.
10. Jones SE, Savin MA, Asmar L, et al. Three-year results of a prospective randomized trial of adjuvant chemotherapy for patients with stage I-III operable, invasive breast cancer comparing four courses of doxorubicin/cyclophosphamide to four courses of docetaxel/cyclophosphamide. Proc Am Soc Clin Oncol 2003; 22: abstr 59.
11. Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer. Proc Am Soc Clin Oncol 2003; 22: abstr 12.
12. Martin M, Pienkowski T, Mackey J, et al. TAC improves DFS and OS over FAC in node positive early breast-cancer patients, BCIRG001. In: San Antonio Breast Cancer Symposium; Dec 3-6, 2003; San Antonio, TX: abstr 43.
13. Henderson IC Berry DA Demetri GD et al. Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 2003 976-983
14. Buzdar AU Singletary SE Valero V et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial Clin Cancer Res 8 2002 1073-1079
15. Liddle JW, Williamson M, Irwig, L. Method for evaluating research and guideline evidence. Sydney: NSW Health Department; December, 1996. http://www.health.nsw.gov.au/public-health/merge/merge.html (accessed November, 2003).
16. Citron ML Berry DA Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 2003 1431-1439
17. Jones SE, Savin M, Holmes FA, et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage I-III operable, invasive breast cancer comparing four courses of adriamycin/cyclophosphamide (AC) to four courses of taxotere/cyclophosphamide (TC). Proc Am Soc Clin Oncol 2001; 20: abstr 128.
18. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21: abstr 141.
19. De Laurentis M. Sequential epirubicin-docetaxel-CMF regimen as adjuvant therapy of early breast cancer: preliminary results of the Taxit-216 multicentre phase III trial. Proc Am Soc Clin Oncol 2003; 22: abstr 115.
20. Dieras VF Fumoleau P Romieu G et al. A randomized parallel study of doxorubicin/taxol and doxorubicin/cyclophosphamide as neoadjuvant treatment of breast cancer Breast Cancer Res Treat 50 1998 233 (abstr)
21. Fountzilas GP Papadimitriou C Briassoulis E et al. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel, and CMF vs epirubicin and CMF in high-risk patients with breast cancer Breast Cancer Res Treat 69 2001 249 (abstr)
22. Goim9902. Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive (pN1) breast cancer: a multicenter randomized phase III study. Proc Am Soc Clin Oncol 2001; 20: abstr 1836.
23. Goldstein LJ, O'Neill A, Sparano JA, et al. LVEF assessment of adjuvant doxorubicin/cyclophosphamide (AC) vs doxorubicin/docetaxel (AT) in early stage breast cancer: cardiac safety results of ECOG 2197. Proc Am Soc Clin Oncol 2003; 22: abstr 73.